Abstract
Oral cancer has emerged as an alarming public health problem with increasing incidence and mortality rates all over the world. Therefore, the implementation of newer screening and early detection approaches are of utmost importance which could reduce the morbidity and mortality associated with this disease. Sensitive and specific biomarkers for oral cancer are likely to be most effective for screening, diagnosis, staging and follow-up for this dreaded malignancy. Unlike other deep cancers, oral cancer is located in oral cavity. Hence, the direct contact between saliva and oral cancer lesion makes the measurement of tumor markers in saliva an attractive alternative to serum and tissue testing. The DNA, RNA and protein molecules derived from the living cancer cells can be conveniently obtained from saliva. Thus, salivary biomarkers, a non-invasive alternative to serum and tissue-based biomarkers may be an effective modality for early diagnosis, prognostication and monitoring post therapy status. In the current post-genomic era, various technologies provide opportunities for high-throughput approaches to genomics and proteomics; which have been used to evaluate altered expressions of gene and protein targets in saliva of oral cancer patients. The emerging field of salivary biomarkers has great potentials to prove its clinical significance to combat oral cancer. Hence, we have reviewed importance of several salivary genomics and proteomics biomarkers for oral cancer.
Similar content being viewed by others
References
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.
Subramanian S, Sankaranarayanan R, Bapat B, Somanathan T, Thomas G, Mathew B, et al. Cost-effectiveness of oral cancer screening: results from a cluster randomized controlled trial in India. Bull World Health Organ. 2009;87:200–6.
Misra C, Majumder M, Bajaj S, Ghosh S, Roy B, Roychoudhury S. Polymorphism at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. Mol Carcinog. 2009;48:790–800.
Boyle P, Levin B, editors. World cancer report 2008. Lyon: International Agency for Research on Cancer; 2008. 330 pp.
Patel JB, Shah FD, Shukla SN, Shah PM, Patel PM. Role of nitric oxide and antioxidant enzymes in the pathogenesis of oral cancer. J Cancer Res Ther. 2009;5:247–53.
Slaughter DL, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: clinical implication of multicentric origins. Cancer. 1953;6:963–8.
Mishra M, Mohanty J, Sengupta S, Tripathy S. Epidemiological and clinicopathological study of oral lekoplakia. Indian J Dermatol Venereol Leprol. 2005;71:161–5.
Wu JY, Yi C, Chung HR, Wang DJ, Chang WC, Lee SY, et al. Potential biomarkers in saliva for oral squamous cell carcinoma. Oral Oncol. 2010;46:226–31.
Pink R, Simek J, Vondrakova J, Faber E, Michl P, Pazdera J, et al. Saliva as a diagnostic medium. Biomed Pap Med Fac Univ Palacky Olocouc Czech Repub. 2009;153:103–10.
Messadi DV, Wilder SP, Wolinsky L. Improving oral cancer survival: the role of dental providers. J Calif Dent Assoc. 2009;37:789–98.
Wong DT. Towards a simple, saliva-based test for the detection of oral cancer. ‘oral fluid (saliva), which is the mirror of the body, is a perfect medium to be explored for health and disease surveillance’. Expert Rev Mol Diagn. 2006;6:267–72.
Leston JS, Dios PD. Diagnostic clinical aids in oral cancer. Oral Oncol. 2010;46:418–22.
Shiptzer T, Hamzany Y, Bahar G, Feinmesser R, Savulescu D, Borovoi I, et al. Salivary analysis of oral cancer biomarkers. Br J Cancer. 2009;101:1194–8.
Cassolato SF, Turnbull RS. Xerostomia: clinical aspects and treatment. Gerodontology. 2003;20:64–77.
Brosky ME. The role of saliva in oral health: strategies for prevention and management of xerostomia. J Support Oncol. 2007;5:215–25.
Ahmadi Motamayel F, Davoodi P, Dalband M, Hendi SS. Saliva as a mirror of the body health. DJH. 2010;2:1–15.
Zimmermann BG, Park NJ, Wong DT. Genomic targets in saliva. Ann NY Acad Sci. 2007;1098:184–91.
Jiang J, Park NJ, Hu S, Wong DT. A universal pre-analytic for concurrent stabilization of salivary proteins, RNA and DNA at ambient temperature. Arch Oral Biol. 2009;54:268–73.
Wong DT. Salivary diagnostics powered by nanotechnologies, proteomics and genomics. J Am Dent Assoc. 2006;137:313–21.
Streckfus CF, Dubinsky WP. Proteomic analysis of saliva for cancer diagnosis. Expert Rev Proteomics. 2007;4:329–32.
Streckfus CF, Bigler L, Tucci M, Thigpen JT. A preliminary study of CA l5-3, c-erbB-2, EGFR, cathepsin-D and p53 in saliva among women with breast carcinoma. Cancer Investig. 2000;18:101–19.
Chen DX, Schwartz PE, Li FQ. Salivary and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol. 1990;75:701–14.
Schapher M, Wendler O, Groschl M, Schafer R, Iro H, Zenk J. Salivary leptin as a candidate diagnostic marker in salivary gland tumors. Clin Chem. 2009;55:914–22.
Wu ZZ, Wang JG, Zhang XL. Diagnostic model of saliva protein finger print analysis of patients with gastric cancer. World J Gastroenterol. 2009;15:865–70.
Wong DT, Zhang L, Farrell J, Zhou F, Elashoff D, Gao K, et al. Salivary biomarkers for pancreatic cancer detection [abstract]. J Clin Oncol. 2009;27(Suppl 15S):4630.
Nagler RM. Saliva as a tool for oral cancer diagnosis and prognosis. Oral Oncol. 2009;45:1006–16.
Rhodus NL, Ho V, Miller CS, Myers S, Ondrey F. NF-kB dependent cytokines levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev. 2005;29:42–5.
St John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2004;130:929–35.
Dowling P, Wormald R, Meleady P, Henry M, Curran A, Clynes M. Analysis of the saliva proteome from patients with head and neck squamous cell carcinoma reveals differences in abundance levels of proteins associated with tumor progression and metastasis. J Proteomics. 2008;71:168–75.
Zhong LP, Chen GF, Xu ZF, Zhang X, Ping FY, Zhao SF. Detection of telomerase activity saliva from oral squamous cell carcinoma patients. Int J Oral Maxillofac Surg. 2005;34:566–70.
Franzmann EJ, Reategui EP, Carraway KL, Hamilton KL, Weed DT, Goodwin WJ. Salivary soluble CD44: a potential molecular marker for head and neck cancer. Cancer Epidemiol Biomark Prev. 2005;14:735–9.
Liao PH, Chang YC, Huang MF, Tai KW, Chou MY. Mutation of p53 gene codon 63 in saliva as a molecular marker for oral squamous cell carcinoma. Oral Oncol. 2000;36:272–6.
Warnakulasuriya S, Soussi T, Maher R, Johnson N, Tavassoli M. Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 in sera and saliva of the patients. J Pathol. 2000;192:52–7.
Sainger RN, Shah MH, Desai AA, Shukla SN, Shah PM, Telang SD, et al. Clinical significance of serum p53 antibodies in oral cancer. Tumori. 2006;92:134–9.
Yamazaki Y, Chiba I, Ishikawa M, Satoh C, Notani K, Ohiro Y, et al. Serum p53 antibodies as a prognostic indicator in oral squamous cell carcinoma. Odontology. 2008;96:32–7.
El-Naggar AK, Mao L, Staerkel G, Coombes MM, Tucker SL, Luna MA, et al. Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening. J Mol Diagn. 2001;3:164–70.
Bahar G, Feinmesser R, Shpitzer T, Popovtzer A, Nagler RM. Salivary analysis in oral cancer patients: DNA and protein oxidation, reactive nitrogen species, and antioxidant profile. Cancer. 2007;109:54–9.
Sato J, Goto J, Murata T, Kitamori S, Yamazaki Y, Satoh A, et al. Changes in saliva interleukin-6 levels in patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110:330–6.
Brailo V, Vacicevic-Boras V, Cekic-Arambasin A, Alajbeg IZ, Milenovic A, Lukac J. The significance of salivary interleukin 6 and tumor necrosis factor alpha in patients with oral leukoplakia. Oral Oncol. 2006;42:370–3.
Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, Fowler KE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2008;113:750–7.
Zhao M, Rosemenbaum E, Carvalho AL, Koch W, Jiang WW, Sidransky D, et al. Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer. Int J Cancer. 2005;117:605–10.
Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, et al. Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res. 2008;14:6246–52.
de Jong EP, Xie H, Onsongo G, Stone MD, Chen XB, Kooren JA, et al. Quantitative proteomics Revels myosin, actin as promising saliva biomarkers for distinguishing pre-malignant, malignant oral lesions. PLoS One. 2010;5:e11148.
Jou YJ, Lin CD, Lai CH, Chen CH, Kao JY, Chen SY, et al. Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer. Anal Chim Acta. 2010;681:41–8.
Zimmermann BG, Wong DT. Salivary mRNA targets for cancer diagnostics. Oral Oncol. 2008;44:425–9.
Viet CT, Schmidt BL. Methylation array analysis of preoperative and postoperative saliva DNA in oral cancer patients. Cancer Epidemiol Biomark Prev. 2008;17:3603–11.
Nakahara Y, Shintani S, Mihara M, Hino S, Hamakawa H. Detection of p16 promoter methylation in serum of oral cancer patients. Int J Oral Maxillofac Surg. 2006;35:362–5.
Viet CT, Jordan RC, Schmidt BL. DNA promoter hypermethylation in saliva for the early diagnosis of oral cancer. J Calif Dent Assoc. 2007;35:844–9.
Wei F, Patel P, Liao W, Chaudhry K, Zhang L, Garcia MA, et al. Electrochemical sensor for multiplex biomarkers detection. Clin Cancer Res. 2009;15:4446–52.
Brinkmann O, Kastratovic DA, Dimitrijevic MV, Konstantinovic VS, Jelovac DB, Antic J, et al. Oral squamous cell carcinoma detection by salivary biomarkers in a Serbian population. Oral Oncol. 2011;47:51–5.
Vairaktaris E, Yapijakis C, Serefoglou Z, Avgoustidis D, Critselis E, Spyridonidou S, et al. Gene expression polymorphisms of interleukins-1 beta, -4, -6, -8, -10, and tumor necrosis factors-alpha, -beta: regression analysis of their effect upon oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2008;134:821–32.
Yapijakis C, Vairaktaris E, Vassiliou S, Vylliotis A, Nkenke E, Nixon AM, et al. The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer. J Cancer Res Clin Oncol. 2007;133:787–91.
Sabitha K, Reddy MV, Jamil K. Smoking related risk involved in individuals carrying genetic variants of CYP1A1 gene in head and neck cancer. Cancer Epidemiol. 2010;34:587–92.
Gatoo MA, Siddiqui M, Farhan AK, Kozgar MI, Owais M. Oral cancer and gene polymorphisms: international status with special reference to India. Asian J Biochem. 2011;6:113–21.
Anantharaman D, Chaubal PM, Kannan S, Bhisey RA, Mahimkar MB. Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians: tobacco exposure as a risk modulator. Carcinogenesis. 2007;28:1455–62.
Sainger RN, Shah FD, Telang SD, Shah PM, Patel PS. Telomere attrition and telomerase activity are associated with GSTM1 polymorphism in oral cancer. Cancer Biomark. 2009;5:189–95.
Patel BP, Shah PM, Rawal UM, Desai AA, Shah SV, Rawal RM, et al. Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma. J Surg Oncol. 2005;90:81–8.
Patel BP, Shah SV, Shukla SN, Shah PM, Patel PS. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck. 2007;29:564–72.
Singh RD, Haridas N, Patel JB, Shah FD, Shukla SN, Shah PM, et al. Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer. Ind J Clin Biochem. 2010;25:250–9.
Patel PS, Raval GN, Rawal RM, Patel MM, Balar DB, Patel DD. Importance of glycoproteins in human cancer. Indian J Biochem Biophys. 1997;34:226–33.
Raval GN, Patel DD, Parekh LJ, Patel JB, Shah MH, Patel PS. Evaluation of serum sialic acid, sialyltransferase and sialoproteins in oral cavity cancer. Oral Dis. 2003;9:119–28.
Rajpura KB, Patel PS, Chawda JG, Shah RM. Clinical significance of total and lipid bound sialic acid levels in oral-precancerous conditions and oral cancer. J Oral Pathol Med. 2005;34:263–7.
Shah MH, Telang SD, Shah PM, Patel PS. Tissue and serum α2-3- and α2-6-linkage specific sialylation changes in oral carcinogenesis. Glycoconjug J. 2008;25:279–90.
Acknowledgment
Our ongoing work on salivary biomarkers is partially funded by research project grants from Indian Council of Medical Research (ICMR, Grant no.: 5/13/95/2003-NCD III) and Gujarat Cancer Society, Ahmedabad (Grant no.: RE/28/BRD 1/09). The authors are also thankful to The Gujarat Cancer and Research Institute for administrative support and allowing to use the clinical material.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shah, F.D., Begum, R., Vajaria, B.N. et al. A Review on Salivary Genomics and Proteomics Biomarkers in Oral Cancer. Ind J Clin Biochem 26, 326–334 (2011). https://doi.org/10.1007/s12291-011-0149-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12291-011-0149-8